Literature DB >> 7448462

The prognostic significance of functional tests in cryptogenic fibrosing alveolitis.

V Jezek, J Fucik, A Michaljanic, L Jezkova.   

Abstract

Fifty-six patients with kryptogenic fibrosing alveolitis were followed up during 6.3 years (from 1.5 to 19.3 years) after their first functional examination including cardiac catheterization. Twenty-two out of 56 patients died during the follow-up. The significance of individual functional tests as predictors of the survival was evaluated by means of actuarial survival probability curves. Four variables were predictive for nonsurvival: a mean pulmonary arterial pressure exceeding 30 mmHg, a vital capacity of 60% of the predicted value or lower, a CO diffusing capacity at rest less than 40% of the predicted value, an age at first symptoms over 30 years. Other variables were not significantly predictive for a given time of follow-up. A simple prognostic score derived from predictive variables was able to separate the subgroup of patients with unfavourable short-term prognosis. Among significantly predictive variables, a resting pulmonary arterial pressure over 30 mmHg appears to be the most important.

Entities:  

Mesh:

Year:  1980        PMID: 7448462

Source DB:  PubMed          Journal:  Bull Eur Physiopathol Respir        ISSN: 0395-3890


  5 in total

Review 1.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis.

Authors:  Xueren Li; Shouchun Peng; Luqing Wei; Zhenhua Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  Pulmonary function testing in idiopathic interstitial pneumonias.

Authors:  Fernando J Martinez; Kevin Flaherty
Journal:  Proc Am Thorac Soc       Date:  2006-06

Review 4.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28

5.  Pirfenidone treatment of idiopathic pulmonary fibrosis.

Authors:  Ye Gan; Erica L Herzog; Richard H Gomer
Journal:  Ther Clin Risk Manag       Date:  2011-02-08       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.